(A) TP53 expression levels are elevated in TP53-mutant and nonmutant HNSC samples compared to normal tissues. حسب Ashraf Attia Mahmoud (21262201)

الموضوعات:

Type of Mutations. حسب Ashraf Attia Mahmoud (21262201)

الموضوعات:

Supplemental Figure S2 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma حسب Nail Fatkhutdinov (14934183)

Data Supplement from Centmitor-1, a Novel Acridinyl-Acetohydrazide, Possesses Similar Molecular Interaction Field and Antimitotic Cellular Phenotype as Rigosertib, ON 01910.Na حسب Jenni H.E. Mäki-Jouppila (15067084)

Data Supplement from Centmitor-1, a Novel Acridinyl-Acetohydrazide, Possesses Similar Molecular Interaction Field and Antimitotic Cellular Phenotype as Rigosertib, ON 01910.Na حسب Jenni H.E. Mäki-Jouppila (15067084)

Figure S6 from Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib حسب Lei Zhu (14951404)

الموضوعات:

Figure S5 from Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib حسب Lei Zhu (14951404)

الموضوعات:

FIGURE 2 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects حسب Alexandria P. Eiken (18597722)

Supplementary Figure 3 from DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with <i>In Silico</i> Analysis to Identify Novel Therape... حسب Allison R. Hanaford (15003641)

DataSheet_1_Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics.docx حسب James D. Sexton (8432454)

"…Introduction<p>The majority of contemporary psychedelic research has focused on ayahuasca, lysergic acid diethylamide, and psilocybin, though there are hundreds of novel psychedelic compounds that may have clinical utility. …"

An increase in resource competition within a community results in a decrease in invasion resistance. حسب Suraya Muzafar (20141845)

Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders حسب Diane Nugent (14796787)

"…</p> <p>WG3 identified three focus areas with the potential to advance the needs of all people with ultra-rare inherited BDs and scored the feasibility, impact, and risk of priority initiatives, including 13 in systems biology and mechanistic science; 2 in clinical research, data collection, and research infrastructure; and 5 in the regulatory process for novel therapeutics and required data collection.…"

Supplementary Figures from RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer حسب Yajing Liu (728964)

الموضوعات:

Figure 5 from Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma حسب Yichi Zhang (20458547)

الموضوعات:

Supplementary Figures S1-S11 from The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer حسب Fang Fang (38179)

Shree Vijayaswathi Senthil Kumar:Calcium Signalling: A novel platform for screening anti-obesity therapeutics حسب Shree Vijayaswathi Senthil Kumar (8487333)

Supplementary Figure S8 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas حسب Nazia Chaudhary (20972310)

Supplementary Table S17 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution حسب Iros Barozzi (15113515)

الموضوعات:

Supplementary Table S3 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution حسب Iros Barozzi (15113515)

الموضوعات:

Supplemental Figure S2 from A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients حسب Yuna Guo (780568)